# Geron Corp: overview

GERN · Nasdaq · CIK 886744 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gern.md) · [Financials](/companies/gern/financials.md) · [Filings](/companies/gern/filings.md) · [Insiders](/companies/gern/insiders.md)

Latest reported revenue: [$57.5m](/filings/0000886744-26-000037.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000886744-26-000037).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [28.3](/filings/0000886744-25-000071.md) | not reported | [39.6](/filings/0000886744-26-000032.md) | [49.0](/filings/0000886744-26-000037.md) | [47.2](/filings/0000886744-25-000071.md) | not reported | [51.8](/filings/0000886744-26-000032.md) | [57.5](/filings/0000886744-26-000037.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(99.8%)](/filings/0000886744-25-000071.md) | not reported | [(42.2%)](/filings/0000886744-26-000032.md) | [(25.4%)](/filings/0000886744-26-000037.md) | [(29.4%)](/filings/0000886744-25-000071.md) | not reported | [0.3%](/filings/0000886744-26-000032.md) | [(21.7%)](/filings/0000886744-26-000037.md) |
| Net margin | % | [(93.5%)](/filings/0000886744-25-000071.md) | not reported | [(50.1%)](/filings/0000886744-26-000037.md) | [(33.4%)](/filings/0000886744-26-000037.md) | [(39.0%)](/filings/0000886744-25-000071.md) | not reported | [(7.0%)](/filings/0000886744-26-000037.md) | [(29.0%)](/filings/0000886744-26-000037.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0000886744-25-000071.md) | not reported | [(0.03)](/filings/0000886744-26-000032.md) | [(0.02)](/filings/0000886744-26-000037.md) | [(0.03)](/filings/0000886744-25-000071.md) | not reported | [(0.01)](/filings/0000886744-26-000032.md) | [(0.02)](/filings/0000886744-26-000037.md) |
| Free cash flow | $m | [(58.9) d](/filings/0000886744-25-000071.md) | [(44.1) d](/filings/0000886744-26-000008.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.4](/filings/0000950170-24-022056.md) | [0.6](/filings/0000950170-24-022056.md) | [0.2](/filings/0000950170-24-022056.md) | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(8183.7%)](/filings/0000950170-24-022056.md) | [(23246.6%)](/filings/0000950170-25-027982.md) | [(81832.9%)](/filings/0000886744-26-000008.md) | not reported | not reported |
| Net margin | % | [(8335.4%)](/filings/0000950170-24-022056.md) | [(23808.9%)](/filings/0000950170-25-027982.md) | [(77690.7%)](/filings/0000886744-26-000008.md) | not reported | not reported |
| Diluted EPS | $ per share | [(0.35)](/filings/0000950170-24-022056.md) | [(0.37)](/filings/0000950170-25-027982.md) | [(0.32)](/filings/0000886744-26-000008.md) | [(0.27)](/filings/0000886744-26-000008.md) | [(0.13)](/filings/0000886744-26-000008.md) |
| Free cash flow | $m | [(95.8)](/filings/0000950170-24-022056.md) | [(128)](/filings/0000950170-25-027982.md) | [(169)](/filings/0000886744-26-000008.md) | [(219)](/filings/0000886744-26-000008.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gern/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $62.9m | 49,115,571 |  | Added +1,795,792 |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $54.8m | 42,809,751 |  | Reduced −20,961,615 |
| [Soleus Capital Management, L.P.](/funds/1802630.md) | 2026-06-30 | $54.8m | 42,808,659 |  | Added +1,300,000 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $45.9m | 35,856,671 |  | Added +5,359,488 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $37.2m | 29,038,928 |  | Added +7,462,359 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $34.9m | 27,250,215 |  | Added +581,186 |
| [Clearbridge Investments, LLC](/funds/1348883.md) | 2026-06-30 | $25.2m | 19,648,853 |  | Added +28,533 |
| [Eversept Partners, LP](/funds/1697013.md) | 2026-06-30 | $24.0m | 18,717,422 |  | Reduced −117,461 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $21.3m | 16,633,368 |  | Added +5,456,777 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $18.6m | 14,555,954 |  | Added +885,169 |

## Recent filings

[All 1,069 filings](/companies/gern/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 10:05 ET | [8-K](/filings/0001193125-26-336508.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336508 |
| 2026-08-05 | 20:41 ET | [10-Q](/filings/0000886744-26-000037.md) | Quarterly report, period 2026-06-30 | 0000886744-26-000037 |
| 2026-05-27 | 20:01 ET | [8-K](/filings/0001193125-26-241842.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-241842 |
| 2026-05-06 | 20:49 ET | [10-Q](/filings/0000886744-26-000032.md) | Quarterly report, period 2026-03-31 | 0000886744-26-000032 |
| 2026-04-07 | 20:30 ET | [DEF 14A](/filings/0000886744-26-000024.md) | Proxy statement, period 2026-05-20 | 0000886744-26-000024 |
| 2026-03-26 | 12:18 ET | [8-K](/filings/0001193125-26-125151.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-125151 |
| 2026-03-02 | 12:11 ET | [10-K](/filings/0000886744-26-000008.md) | Annual report, period 2025-12-31 | 0000886744-26-000008 |
| 2026-02-25 | 12:15 ET | [8-K](/filings/0001193125-26-068523.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-068523 |
| 2026-01-12 | 13:00 ET | [8-K](/filings/0000886744-26-000003.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000886744-26-000003 |
| 2026-01-06 | 11:01 ET | [8-K](/filings/0001193125-26-003388.md) | 1.01 Entry into a material agreement | 0001193125-26-003388 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000886744-26-000008.md), filed Mar 2, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/30feb46c-93ef-45ac-b3bf-d165abe486f1)

## About the filer

- CIK: 886744
- Tickers: GERN
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.